leisure time -WSS

leisure time

author：focus 2025-09-06 04:13:36 - browse：512

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Why the drug industry's warnings on the IRA's impact fall short

focus

WSS

Information blocking fines are now fair game in health care

Man with guns arrested near Obama home 'attempted to evade' Secret Service: Prosecutors

1 in 4 Americans hadn't contracted COVID by the end of 2022, CDC estimates

Dramatic video released of Russian fighter jets 'harassing' US drones over Syria

Accuser says Kevin Spacey grope wasn't a caress: ‘It was like a cobra ... angry’

Man with guns arrested near Obama home 'attempted to evade' Secret Service: Prosecutors

entertainment

leisure time

leisure time

Heart attack and stroke risk calculators need revising

Israel withdraws forces after 2

Duchenne breakthrough therapy leaves behind pioneering families

Information blocking fines are now fair game in health care

In Memoriam: Notable people who died in 2023

Man pleads guilty to raping Ohio girl who ended up traveling across state lines for abortion

Supreme Court strikes down use of affirmative action

Why the drug industry's warnings on the IRA's impact fall short

How to save PrEP access — and even expand it

A bus careens into a gulch in southern Mexico, leaving 27 people dead

Wikipedia

FDA panel to weigh safety of artificial wombs for preterm births

Accuser says Kevin Spacey grope wasn't a caress: ‘It was like a cobra ... angry’

Chamber of Commerce, DOJ clash in court over drug prices

Transgender sports debate: Physicians say bans are health issue

Pope Francis asks Church to identify 21st

Patients, doctors press FTC to beef up hospital merger scrutiny

focus

focus

knowledge

leisure time